Claims (17)
1. Spoj formule (IV):
ili njegova farmaceutski prihvatljiva sol, pri čemu
R2 je (C1-C3)alkil;
R4 je vodik, (C1-C3)alkil, ili =O;
n je 1 ili 2;
Cy1 je fenil, piperidinil, tetrahidro-2H-tiopiranil 1,1-dioksid, piridinil, piperazinil, azetidinil, imidazolil, tetrahidropiranil, 1,4-dioksanil, piridazinil, pirazolil, pirolidinil, cikloheksil, morfolinil, 6,7-dihidro-5H-pirolo[2,1-c][1,2,4]triazolil, 1,2,3,4-tetrahidro-1,8-naftiridinil, 2,3-dihidro-1H-indenil, ili imidazo[1,2-a]pirimidinil, od kojih je svaki opcionalno zamijenjen sa 1 do 2 grupe neovisno odabrane od R5;
Cy2 je fenil, pirimidinil, cikloheksil, ili piridinil, od kojih je svaki opcionalno zamijenjen sa 1 do 2 grupe neovisno odabrane od R6; i
R5 i R6 su svaki neovisno odabrani od halo, cijano, nitro, amino, hidroksi, karboksi, (C1-C6)alkil, heterociklil, hidroksi(C1-C6)alkil, CO2H, (CH2)1-3COOH, (C1-C3)alkilkarboniloksi, (C3-C6)cikloalkil, hidroksi(C3-C6)cikloalkil, (C4-C7)cikloalkilalkil, (C2-C6)alkenil, halo(C2-C6)alkenil, hidroksi(C2-C6)alkenil, (C2-C6)alkinil, (C3-C6)cikloalkil(C2-C4)alkinil, halo(C1-C6)alkil, halo(C3-C6)cikloalkil, halo(C4-C7)cikloalkilalkil, (C1-C6)alkoksi, (C3-C6)cikloalkoksi, (C4-C7)cikloalkilalkoksi, halo(C1-C6)alkoksi, halo(C3-C6)cikloalkoksi, halo(C4-C7)cikloalkilalkoksi, (C1-C6)alkiltio, (C3-C6)cikloalkitio, (C4-C7)cikloalkilalkiltio, halo(C1-C6)alkiltio, halo(C3-C6)cikloalkitio, halo(C4-C7)cikloalkilalkiltio, (C1-C6)alkilsulfinil, (C3-C6)cikloalkilsulfinil, (C4-C7)cikloalkilalkilsulfinil, halo(C1-C6)alkilsulfonil, halo(C3-C6)cikloalkilsulfinil, halo(C4-C7)cikloalkilalkilsulfinil, (C1-C6)alkilsulfonil, (C3-C6)cikloalkilsulfonil, (C4-C7)cikloalkilalkilsulfonil, halo(C1-C6)alkilsulfonil, halo(C3-C6)cikloalkilsulfonil, halo(C4-C7)cikloalkilalkilsulfonil, (C1-C6)alkilamino, di(C1-C6)alkilamino, (C1-C6)alkoksi(C1-C6)alkoksi, halo(C1-C6)alkoksi(C1-C6)alkoksi, (C1-C6)alkoksikarbonil, H2NCO, H2NSOL2, (C1-C6)alkilaminokarbonil, di(C1-C6)alkilaminokarbonil, (C1-C3)alkoksi(C1-C3)alkilaminokarbonil, heterociklilkarbonil, (C1-C6)alkilaminosulfonil, di(C1-C6)alkilaminosulfonil, heterociklilsulfonil, (C1-C6)alkilkarbonilamino, (C1-C6)alkil-karbonilamino(C1-C6)alkil, (C1-C6)alkilsulfonilamino, (C1-C6)alkilsulfonilamino(C1-C6)alkil, (C1-C6)alkoksikarbonil(C1-C6)alkoksi, (C1-C6)alkoksi(C1-C6)alkil, halo(C1-C6)alkoksi(C1-C6)alkil, hidroksi(C1-C6)alkoksi, aril, heteroaril, oksol, amino(C1-C6)alkil, (C1-C6)alkilamino(C1-C6)alkil, di(C1-C6)alkilamino(C1-C6)alkil amino(C2-C6)alkoksi, (C1-C6)alkilamino(C2-C6)alkoksi, di(C1-C6)alkilamino(C2-C6)alkoksi, (C1-C6)alkilkarbonil, hidroksi(C1-C6)alkilkarbonil, (C1-C6)alkilhidroksikarbonil, (C1-C6)alkilhidroksi(C1-C6)alkil, (C3-C6)cikloalkilkarbonil, (C3-C6)cikloalkilaminokarbonil, {(C3-C6)cikloalkil}{(C1-C6)alkil}aminokarbonil, di(C3-C6)cikloalkilaminokarbonil, (C3-C6)cikloalkilaminosulfonil, {(C3-C6)cikloalkil}{(C1-C6)alkil}aminosulfonil, di(C3-C6)cikloalkilaminosulfonil, cijano(C1-C6)alkil, aminokarbonil(C1-C6)alkil, (C1-C6)alkilaminokarbonil(C1-C6)alkil, di(C1-C6)alkilaminokarbonil(C1-C6)alkil, (C3-C6)cikloalkilaminokarbonil(C1-C6)alkil, {(C3-C6)cikloalkil}{(C1-C6)alkil}aminokarbonil(C1-C6)alkil, [(C1-C6)alkil(C4-C6)heterociclil](C1-C6)alkil, i di(C3-C6)cikloalkilaminokarbonil(C1-C6)alkil.1. Compound of formula (IV):
or a pharmaceutically acceptable salt thereof, wherein
R 2 is (C 1 -C 3 )alkyl;
R 4 is hydrogen, (C 1 -C 3 )alkyl, or =O;
n is 1 or 2;
Cy1 is phenyl, piperidinyl, tetrahydro-2H-thiopyranyl 1,1-dioxide, pyridinyl, piperazinyl, azetidinyl, imidazolyl, tetrahydropyranyl, 1,4-dioxanyl, pyridazinyl, pyrazolyl, pyrrolidinyl, cyclohexyl, morpholinyl, 6,7-dihydro-5H -pyrrolo[2,1-c][1,2,4]triazolyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 2,3-dihydro-1H-indenyl, or imidazo[1,2 -α]pyrimidinyl, each of which is optionally substituted with 1 to 2 groups independently selected from R 5 ;
Cy2 is phenyl, pyrimidinyl, cyclohexyl, or pyridinyl, each of which is optionally substituted with 1 to 2 groups independently selected from R6; and
R5 and R6 are each independently selected from halo, cyano, nitro, amino, hydroxy, carboxy, (C1-C6)alkyl, heterocyclyl, hydroxy(C1-C6)alkyl, CO2H, (CH2)1-3COOH, (C1-C3 )alkylcarbonyloxy, (C3-C6)cycloalkyl, hydroxy(C3-C6)cycloalkyl, (C4-C7)cycloalkylalkyl, (C2-C6)alkenyl, halo(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, (C2 -C6)alkynyl, (C3-C6)cycloalkyl(C2-C4)alkynyl, halo(C1-C6)alkyl, halo(C3-C6)cycloalkyl, halo(C4-C7)cycloalkylalkyl, (C1-C6)alkoxy, ( C3-C6)CycloAlkoxy, (C4-C7)CycloalkylAlkoxy, Halo(C1-C6)Alkoxy, Halo(C3-C6)CycloAlkoxy, Halo(C4-C7)CycloalkylAlkoxy, (C1-C6)Alkylthio, (C3-C6)Cycloalkylthio , (C4-C7)cycloalkylalkylthio, halo(C1-C6)alkylthio, halo(C3-C6)cycloalkylthio, halo(C4-C7)cycloalkylalkylthio, (C1-C6)alkylsulfinyl, (C3-C6)cycloalkylsulfinyl, (C4-C7 )cycloalkylalkylsulfinyl, halo(C1-C6)alkylsulfonyl, halo(C3-C6)cycloalkylsulfinyl, halo(C4-C7)cycloalkylalkylsulfinyl, (C1-C6)alkylsulfonyl, (C3-C6)cycloalkylsulfonyl, (C4-C7)cycloalkylalkylsulfonyl, halo( C1-C6)alkylsulfonyl, halo(C3-C 6) cycloalkylsulfonyl, halo(C4-C7) cycloalkylalkylsulfonyl, (C1-C6) alkylamino, di(C1-C6) alkylamino, (C1-C6) alkoxy(C1-C6) alkoxy, halo(C1-C6) alkoxy(C1- C6)Alkoxy, (C1-C6)Alkoxycarbonyl, H2NCO, H2NSOL2, (C1-C6)Alkylaminocarbonyl, Di(C1-C6)Alkylaminocarbonyl, (C1-C3)Alkoxy(C1-C3)Alkylaminocarbonyl, Heterocyclylcarbonyl, (C1-C6) alkylaminosulfonyl, di(C1-C6)alkylaminosulfonyl, heterocyclylsulfonyl, (C1-C6)alkylcarbonylamino, (C1-C6)alkylcarbonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1- C6)alkyl, (C1-C6)Alkoxycarbonyl(C1-C6)Alkoxy, (C1-C6)Alkoxy(C1-C6)Alkyl, Halo(C1-C6)Alkoxy(C1-C6)Alkyl, Hydroxy(C1-C6) Alkoxy, Aryl, Heteroaryl, Oxol, Amino(C1-C6)alkyl, (C1-C6)Alkylamino(C1-C6)Alkyl, Di(C1-C6)Alkylamino(C1-C6)Alkyl Amino(C2-C6)Alkoxy, (C1-C6)Alkylamino(C2-C6)Alkoxy, Di(C1-C6)Alkylamino(C2-C6)Alkoxy, (C1-C6)Alkylcarbonyl, Hydroxy(C1-C6)Alkylcarbonyl, (C1-C6)Alkylhydroxycarbonyl, ( C1-C6)alkylhydroxy(C1-C6)alkyl, (C3-C6)cycloalkylcarbonyl, (C3-C6) cycloalkylaminocarbonyl, {(C3-C6)cycloalkyl}{(C1-C6)alkyl}aminocarbonyl, di(C3-C6)cycloalkylaminocarbonyl, (C3-C6)cycloalkylaminosulfonyl, {(C3-C6)cycloalkyl}{(C1-C6)alkyl }aminosulfonyl, di(C3-C6)cycloalkylaminosulfonyl, cyano(C1-C6)alkyl, aminocarbonyl(C1-C6)alkyl, (C1-C6)alkylaminocarbonyl(C1-C6)alkyl, di(C1-C6)alkylaminocarbonyl(C1- C6)alkyl, (C3-C6)cycloalkylaminocarbonyl(C1-C6)alkyl, {(C3-C6)cycloalkyl}{(C1-C6)alkyl}aminocarbonyl(C1-C6)alkyl, [(C1-C6)alkyl(C4 -C6)heterocyclyl](C1-C6)alkyl, and di(C3-C6)cycloalkylaminocarbonyl(C1-C6)alkyl.
2. Spoj prema zahtjevu 1, pri čemu je spoj formule (V) ili (VI):
ili
ili njegova farmaceutski prihvatljiva sol.2. The compound according to claim 1, wherein the compound of formula (V) or (VI):
or
or a pharmaceutically acceptable salt thereof.
3. Spoj prema zahtjevu 1 ili 2, pri čemu je spoj Formule (VII):
ili njegova farmaceutski prihvatljiva sol.3. A compound according to claim 1 or 2, wherein the compound of Formula (VII):
or a pharmaceutically acceptable salt thereof.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, pri čemu Cy1 je fenil, piperidinil, tetrahidro-2H-tiopiranil 1,1-dioksid, piridinil, piperazinil, azetidinil, imidazolil, tetrahidropiranil, 1,4-dioksanil, piridazinil, pirazolil, pirolidinil, cikloheksil, morfolinil, 6,7-dihidro-5H-pirolo[2,1-c][1,2,4]triazolil, 1,2,3,4-tetrahidro-1,8-naftiridinil, 2,3-dihidro-1H-indenil, ili imidazo[1,2-a]pirimidinil, od kojih je svaki opcionalno zamijenjen sa 1 do 2 grupe neovisno odabrane od R5, pri čemu je najmanje jedan R5 (C1-C3)alkilsulfonil ili (C1-C3)alkilaminosulfonil. 4. A compound according to any one of claims 1 to 3, wherein Cy1 is phenyl, piperidinyl, tetrahydro-2H-thiopyranyl 1,1-dioxide, pyridinyl, piperazinyl, azetidinyl, imidazolyl, tetrahydropyranyl, 1,4-dioxanyl, pyridazinyl, pyrazolyl , pyrrolidinyl, cyclohexyl, morpholinyl, 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 2, 3-dihydro-1H-indenyl, or imidazo[1,2-a]pyrimidinyl, each of which is optionally substituted with 1 to 2 groups independently selected from R5, wherein at least one R5 is (C1-C3)alkylsulfonyl or (C1 -C3)alkylaminosulfonyl.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, pri čemu je R2 (C1-C3)alkil; i Cy1 je fenil, piridinil, ili piperidinil, od kojih je svaki opcionalno zamijenjen sa 1 do 2 grupe neovisno odabrane od R5, pri čemu je najmanje jedan R5 (C1-C3)alkilsulfonil ili (C1-C3)alkilaminosulfonil. 5. A compound according to any one of claims 1 to 4, wherein R 2 is (C 1 -C 3 )alkyl; and Cy 1 is phenyl, pyridinyl, or piperidinyl, each of which is optionally substituted with 1 to 2 groups independently selected from R 5 , wherein at least one R 5 is (C 1 -C 3 )alkylsulfonyl or (C 1 -C 3 )alkylaminosulfonyl.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, pri čemu je Cy2 cikloheksil opcionalno zamijenjen sa 1 do 2 grupe koje su neovisno odabrane od R6.6. A compound according to any one of claims 1 to 5, wherein Cy2 cyclohexyl is optionally substituted with 1 to 2 groups independently selected from R6.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, pri čemu
R5 je izabran od halo, (C1-C3)alkil, halo(C1-C3)alkil, cijano, hidroksi(C1-C3)alkil, (C1-C3)alkoksikarbonil, (C1-C3)alkilsulfonil, (C1-C3)alkoksi, halo(C1-C3)alkoksi, oksol, hidroksi, (C1-C3)alkilkarbonil, hidroksi(C1-C3)alkilkarbonil, (C1-C3)alkilhidroksikarbonil, (C1-C3)alkilaminosulfonil, (C1-C3)alkilaminokarbonil, di(C1-C3)alkilamino(C2-C6)alkoksi, (C1-C6)alkoksikarbonil, [(C1-C3)alkil(C4-C6)heterociklil](C1-C3)alkil, i (C1-C3)alkilhidroksi(C1-C3)alkil; i
R6 je izabran od halo, (C1-C3)alkil, halo(C1-C3)alkil, cijano, hidroksi(C1-C3)alkil, (C1-C3)alkoksikarbonil, (C1-C3)alkilsulfonil, (C1-C3)alkoksi, halo(C1-C3)alkoksi, oksol, hidroksi, aril(C1-C3)alkoksikarbonil, (C1-C3)alkilhidroksi(C1-C3)alkil, heteroaril, i (C1-C3)alkoksikarbonil.7. A compound according to any one of claims 1 to 6, wherein
R 5 is selected from halo, (C 1 -C 3 )alkyl, halo (C 1 -C 3 )alkyl, cyano, hydroxy (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxycarbonyl, (C 1 -C 3 )alkylsulfonyl, (C 1 -C 3 ) Alkoxy, halo(C1-C3)Alkoxy, oxol, hydroxy, (C1-C3)alkylcarbonyl, hydroxy(C1-C3)alkylcarbonyl, (C1-C3)alkylhydroxycarbonyl, (C1-C3)alkylaminosulfonyl, (C1-C3)alkylaminocarbonyl, di(C1-C3)alkylamino(C2-C6)alkoxy, (C1-C6)alkoxycarbonyl, [(C1-C3)alkyl(C4-C6)heterocyclyl](C1-C3)alkyl, and (C1-C3)alkylhydroxy( C1-C3)alkyl; and
R 6 is selected from halo, (C1-C3)alkyl, halo(C1-C3)alkyl, cyano, hydroxy(C1-C3)alkyl, (C1-C3)alkoxycarbonyl, (C1-C3)alkylsulfonyl, (C1-C3) alkoxy, halo(C1-C3) alkoxy, oxol, hydroxy, aryl(C1-C3) alkoxycarbonyl, (C1-C3) alkylhydroxy(C1-C3) alkyl, heteroaryl, and (C1-C3) alkoxycarbonyl.
8. Spoj prema bilo kojem od zahtjeva 1 do 7, pri čemu
R5 je izabran od halo, (C1-C3)alkoksi, hidroksi, (C1-C3)alkil, hidroksi(C1-C3)alkil, halo(C1-C3)alkil, (C1-C6)alkoksikarbonil, di(C1-C3)alkilamino(C2-C6)alkoksi, [(C1-C3)alkil(C4-C6)heterociklil](C1-C3)alkil, oksol, (C1-C3)alkilkarbonil, (C1-C3)alkilaminosulfonil, (C1-C3)alkilsulfonil, i cijano; i
R6 je izabran od halo(C1-C3)alkil, (C1-C3)alkoksi, halo, cijano, (C1-C3)alkoksikarbonil, (C1-C3)alkilhidroksi(C1-C3)alkil, hidroksi(C1-C3)alkil, i halo(C1-C3)alkoksi.8. A compound according to any one of claims 1 to 7, wherein
R5 is selected from halo, (C1-C3) alkoxy, hydroxy, (C1-C3) alkyl, hydroxy(C1-C3) alkyl, halo(C1-C3) alkyl, (C1-C6) alkoxycarbonyl, di(C1-C3 )alkylamino(C2-C6)Alkoxy, [(C1-C3)alkyl(C4-C6)heterocyclyl](C1-C3)alkyl, oxole, (C1-C3)alkylcarbonyl, (C1-C3)alkylaminosulfonyl, (C1-C3 )alkylsulfonyl, and cyano; and
R6 is selected from halo(C1-C3)alkyl, (C1-C3)alkoxy, halo, cyano, (C1-C3)alkoxycarbonyl, (C1-C3)alkylhydroxy(C1-C3)alkyl, hydroxy(C1-C3)alkyl , and halo(C1-C3) alkoxy.
9. Spoj prema bilo kojim zahtjevima 1 do 8, pri čemu R5 je izabran od halo, cijano, (C1-C3)alkil, (C1-C3)alkilaminosulfonil, i (C1-C3)alkilsulfonil; i R6 je izabran od halo(C1-C3)alkil, (C1-C3)alkoksi, halo, cijano, (C1-C3)alkoksikarbonil, i halo(C1-C3)alkoksi.9. A compound according to any of claims 1 to 8, wherein R 5 is selected from halo, cyano, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkylaminosulfonyl, and (C 1 -C 3 )alkylsulfonyl; and R 6 is selected from halo(C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, halo, cyano, (C 1 -C 3 ) alkoxycarbonyl, and halo(C 1 -C 3 ) alkoxy.
10. Spoj prema bilo kojem od zahtjeva 1 do 9, pri čemu
Cy1 je
R10 je (C1-C3)alkil ili (C1-C3)alkilamino; i
Z je CH ili N.10. A compound according to any one of claims 1 to 9, wherein
Cy1 is
R 10 is (C 1 -C 3 )alkyl or (C 1 -C 3 )alkylamino; and
Z is CH or N.
11. Spoj prema bilo kojem od zahtjeva 1 do 5 i 7 do 10, pri čemu
R12 je (C1-C3)alkoksikarbonil, halo, dihalo, (C1-C3)alkoksi, ili halo(C1-C3)alkil;
R13 je halo ili halo(C1-C3)alkil; i
R14 je halo, cijano, halo(C1-C3)alkil, ili halo(C1-C3)alkoksi.11. A compound according to any one of claims 1 to 5 and 7 to 10, wherein
R 12 is (C 1 -C 3 )alkoxycarbonyl, halo, dihalo, (C 1 -C 3 )alkoxy, or halo(C 1 -C 3 )alkyl;
R 13 is halo or halo(C 1 -C 3 )alkyl; and
R 14 is halo, cyano, halo(C 1 -C 3 )alkyl, or halo(C 1 -C 3 )alkoxy.
12. Spoj prema zahtjevu 11, pri čemu R12 do R14 su svaki CF3. 12. A compound according to claim 11, wherein R12 to R14 are each CF3.
13. Spoj prema bilo kojem od zahtjeva 1 do 12, pri čemu R2 je izopropil. 13. A compound according to any one of claims 1 to 12, wherein R 2 is isopropyl.
14. Spoj prema zahtjevu 1, pri čemu je spoj formule:
ili njegova farmaceutski prihvatljiva sol.14. The compound according to claim 1, wherein the compound is of the formula:
or a pharmaceutically acceptable salt thereof.
15. Farmaceutski sastav koji obuhvaća spoj prema bilo kojem od zahtjeva 1 do 14, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivi nosač.15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
16. Spoj prema bilo kojem od zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, ili sastav prema zahtjevu 15, za upotrebu u liječenju bolesti ili poremećaja koji je izabran iz grupe koja obuhvaća astmu, kroničnu opstruktivnu bolest pluća (COPD), bronhitis, alergijski rinitis, atopični dermatitis, kontaktni dermatitis, akne, cističnu fibrozu, odbacivanje alografta, multiplu sklerozu, sklerodermu, artritis, reumatoidni artritis, dječji reumatoidni artritis, osteoartritis, ankilozantni spondilitis, sistemski eritemski lupus (SLE), psorijazu, Hashimotovu bolest, pankreatitis, autoimuni dijabetes, tip I dijabetes, autoimunsku bolest oka, ulcerativni kolitis, Chronovu bolest, regionalni enteritis, upalnu bolest crijeva (IBD), sindrom upale crijeva (IBS), Sjögrenov sindrom, optički neuritis, pretilost, hepatosteatozu, upalu povezanu sa adipoznim tkivom, inzulinsku rezistenciju, tip II dijabestes, optički neuromijelitis, miasteniju gravis, starosnu makularnu degeneraciju, sindrom suhog oka, uveitis, Guillain-Barré sindrom, psorijazu, psorijazni artritis (PsA), astmu rezistentnu na steroide, Gravesovu bolest, skleritis, tešku depresiju, sezonski afektivni poremećaj, PTSD, bipolarni poremećaj, autizam, epilepsiju, Alzheimerovu bolest, CNS poremećaje povezane sa izmijenjenim snom i/ili cirkadijskim ritmovima, endometriozu, sindrom opstruktivne apnee u snu (OSAS), Behçetovu bolest, dermatomiozitis, polimiocitis, transplantacijsku bolest, primarnu bilijarnu cirozu, fibrozu jetre, ne-alkoholnu bolest masne jetre (NAFLD), sarkoidozu, primarni sklerozni holangitis, autoimunu bolest štitnjače, autoimuni poliendokrini sindrom tipa I, autoimuni poliendokrini sindrom tipa II, celijakiju, neuromijelitis, dječji idiopatski artritis, sistemsku sklerozu, infarkt miokarda, plućnu hipertenziju, osteoartritis, kožne lišmanijaze, sinonazalne polipe, i rakove. 16. A compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, or a composition according to claim 15, for use in the treatment of a disease or disorder selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), bronchitis, allergic rhinitis, atopic dermatitis, contact dermatitis, acne, cystic fibrosis, allograft rejection, multiple sclerosis, scleroderma, arthritis, rheumatoid arthritis, pediatric rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), psoriasis, Hashimoto's disease, pancreatitis, autoimmune diabetes, type I diabetes, autoimmune eye disease, ulcerative colitis, Crohn's disease, regional enteritis, inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), Sjögren's syndrome, optic neuritis, obesity, hepatosteatosis, inflammation associated with adipose tissue, insulin resistance, type II diabetes, neuromyelitis optica, myasthenia gravis, age-related macular degeneration, dry syndrome eye disease, uveitis, Guillain-Barré syndrome, psoriasis, psoriatic arthritis (PsA), steroid-resistant asthma, Graves' disease, scleritis, major depression, seasonal affective disorder, PTSD, bipolar disorder, autism, epilepsy, Alzheimer's disease, CNS related disorders with altered sleep and/or circadian rhythms, endometriosis, obstructive sleep apnea syndrome (OSAS), Behçet's disease, dermatomyositis, polymyositis, transplant disease, primary biliary cirrhosis, liver fibrosis, non-alcoholic fatty liver disease (NAFLD), sarcoidosis, primary sclerosing cholangitis, autoimmune thyroid disease, autoimmune polyendocrine syndrome type I, autoimmune polyendocrine syndrome type II, celiac disease, neuromyelitis, childhood idiopathic arthritis, systemic sclerosis, myocardial infarction, pulmonary hypertension, osteoarthritis, cutaneous leishmaniasis, sinonasal polyps, and cancers.
17. Spoj prema bilo kojem od zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, ili sastav prema zahtjevu 15, za upotrebu u liječenju bolesti ili poremećaja koji je izabran iz grupe koja se sastoji od astme, atopičnog dermatitisa, akni, Chronove bolesti, regionalnog enteritisa, ulcerativnog kolitisa, Sjögrenovog sindroma, uveitisa, Behçetove bolesti, dermatomiozitisa, multiple skleroze, ankilozantnog spondilitisa, sistemskog lupusa eritematozusa (SLE), skleroderme, psorijaze, psorijaznog artritisa (PsA), astme rezistentne na steroid, i reumatoidnog artritisa.17. A compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, or a composition according to claim 15, for use in the treatment of a disease or disorder selected from the group consisting of asthma, atopic dermatitis, acne, Crohn's disease, regional enteritis, ulcerative colitis, Sjögren's syndrome, uveitis, Behçet's disease, dermatomyositis, multiple sclerosis, ankylosing spondylitis, systemic lupus erythematosus (SLE), scleroderma, psoriasis, psoriatic arthritis (PsA), steroid-resistant asthma, and rheumatoid arthritis.